I
nflammatory bowel disease (IBD) is thought to be the result of an aberrant immunological response to commensal microbes in genetically susceptible individuals. [1] [2] [3] [4] Serum antibodies against microbes or self-antigens have been used as markers for the disease phenotype and disease course in Crohn's disease (CD) and ulcerative colitis (UC). [5] [6] [7] [8] [9] [10] [11] Although the mechanism is unclear, these serological biomarkers may be the consequence of injury to the gut and/or increased permeability to the luminal microbes or other agents. Anti-Saccharomyces cerevisiae antibodies (ASCA) and perinuclear antineutrophil cytoplasmic antibodies (pANCA) were the first extensively characterized serological IBD markers. 12, 13 Additionally, there are other serum biomarkers for diagnostic use or for assessing their association with disease complication in IBD, including antibodies against outer membrane porin C (anti-OmpC), Pseudomonas fluorescens bacterial sequence I2 (anti-I2), and bacterial flagellin (anti-CBir 1).
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(anti-laminaribioside carbohydrate antibody), ACCA (antichitobioside carbohydrate antibody), Anti-L (anti-laminarin), and Anti-C (anti-chitin). 17, 18 Several independent studies have reported on the diagnostic ability of these markers and their association with disease complication (see review 33 ), but the results and conclusions vary between studies. Therefore, a meta-analysis of these data is necessary.
We aimed to perform a systematic review and metaanalysis of the diagnostic ability of the anti-glycan antibodies to differentiate IBD from non-IBD and CD from UC, as well as their association with disease complications and/ or the need for surgery in IBD.
MATERIALS AND METHODS

Search Strategy
The most recent search of Medline was performed in May 2011. The search strategy was: (''Inflammatory Bowel Disease'' or ''Crohn'' or ''Ulcerative Colitis'') and Glycan and Antibody. No language restrictions were made, but we did not identify any non-English studies that met the inclusion criteria based on the titles and abstracts.
Inclusion and Exclusion Criteria
Included studies compared at least two of the six antiglycan antibody markers (ASCA [or gASCA], AMCA, ALCA, ACCA, Anti-L, and Anti-C) in human subjects with at least one of the following outcomes: differentiating IBD from non-IBD; CD from UC; IBD-related complication; or need for IBD-related surgery. gASCA, so termed in the anti-glycan panel from Glycominds (Simi Valley, CA), is equivalent to ASCA termed in other assays made by other commercial sources. We excluded reviews, case reports, and editorials.
Review Processes and Data Abstraction
Title, abstract, and full article selection were performed independently by two reviewers (A.K., S.H.) with conflicts resolved by consensus adjudication.
Outcomes
The primary outcomes of interest were to differentiate IBD from non-IBD and CD from UC. Secondary outcome of interest was to analyze and compare the association of these markers with disease course including complications and/or need for surgery in IBD.
Statistical Analysis
Pooled sensitivity and specificity were calculated using a DerSimonian and Laird random-effects model and summarized with the diagnostic odds ratio (DOR), which compares the odds of being correctly classified (true positive or negative) to being incorrectly classified (false positive or negative). The DOR was calculated for individual anti-glycan markers as well as combinations of markers. The only combination possible for meta-analysis was 2 markers compared to 1 marker. I-squared was used to assess the statistical heterogeneity with values of 50% and greater indicating significant heterogeneity. We used MetaAnalyst, Beta 3.1 software 19 for Windows and Stata 11.0 for all analyses. 20 
RESULTS AND DISCUSSION
Study Characteristics
The studies included at each level of review and the reasons for exclusions are illustrated in Figure  F1 1. Fourteen studies were included in the systematic review (Table  T1  1) . Of these included studies, only nine were included in the metaanalysis due to possible overlap of patient populations (Table  1 highlights the excluded studies, and Table  T2  2 lists the studies included in the meta-analysis). We contacted the corresponding authors of the five studies, [21] [22] [23] [24] [25] and received one reply confirming that the study had an overlapping patient population. Therefore, we included the study with the largest sample size of those studies. All 14 included studies were retrospective and occurred at referral centers (Table 1) . Twelve studies were conducted in Europe, one in Israel, and one in Canada. Only two of the studies 26, 27 included in the meta-analysis reported the sensitivities and specificities of anti-C and anti-L.
The pooled analyses of the nine studies included in the meta-analysis are summarized in Table  T3 3. We also compared the 9 versus 14 studies, and found the DORs of ASCA for all the different diagnostic differentiation outcomes were higher when all 14 studies (Supporting Table  1 ) were analyzed together, as compared to 9 ( Table 3) . The DORs for surgery, complications, and combination of markers remain similar. Hence, the conclusions from the 14 studies are the same as that of the 9 studies included in the meta-analysis.
Patient Characteristics
The mean age of the IBD patients ranged from 29 to 47 years, with mean duration of disease ranging from 5 to 12 years (Table 2) . One study included patients under 18 years of age, 27 but did not report the pediatric results separately from the adults. The healthy and other gastrointestinal disease controls were generally older than the CD and UC patients ( Table 2 ).
Differentiation of Diagnosis
Overall, our analysis indicates that ASCA is the dominant factor in this anti-glycan marker panel in terms of the DOR for diagnostic differentiation, while no specific marker is prominent for disease behavior or surgery. ASCA has the highest sensitivity compared to the other anti-glycan markers for diagnosis of both CD (52.8%-56.6% vs. 15.0%-27.8%) and CD-related surgery (60.2% vs. 43.9%-47.3%) or complications (70.8% vs. 42.3%-54.5%). In terms of specificity, however, all single markers performed similarly (88%-95%; Table 3 ; Fig.  F2 2). A combination of 2 anti-glycan markers performed better than individual markers for CD-related surgery, but was no better for complications or for differentiating CD from UC. Although the association of the number of positive anti-glycan markers with disease course could not be meta-analyzed, as stated above, it is important to note that an increasing number of positive anti-glycan antibodies was shown to be associated with penetrating phenotype, perianal disease, ileocolitis disease, and need for surgery. 27 IBD vs. Healthy (Two Studies Included in Metaanalysis; Table 3) Individually, ASCA had the highest sensitivity of 44% (specificity 96.4%), while ALCA had the highest specificity of 96.8% (sensitivity 15%). ASCA had the highest DOR for differentiating IBD from healthy (DOR 21.1; confidence interval [CI] 1.8-247.3). 9, 27 Only one study 27 provided data for anti-L (DOR 13.4) and anti-C (DOR 3.6). No study reported the combination of markers for this outcome.
CD vs. Healthy (Six Studies Included in Metaanalysis; Table 3) As shown in Table 3 , individually ASCA had the highest sensitivity of 53.0% (specificity 70.4%), while ALCA had the highest specificity of 87.2% (sensitivity 26.0%). ASCA had the highest DOR for differentiating CD from healthy (DOR 2.7; CI 0.3-21.6). 6, 26, 28, 29 Only one study 26 reported on anti-L (DOR 2.8) and anti-C (DOR 2.4). No study reported the combination markers. No study reported UC versus healthy.
CD vs. OGD (Other Gastrointestinal Disorders) (Four Studies Included in Meta-analysis; Table 3)
As shown in Table 3 , for individual markers ASCA had the highest sensitivity of 52.8% (specificity 90.9%), while AMCA had the highest specificity of 94.7% but had the lowest sensitivity (17.4%). ASCA had the highest DOR for differentiating CD from OGD (DOR 10.3; CI 5.0-21.0). 6, 26, 28, 29 Only one study 26 reported on anti-L (DOR 2.8) and anti-C (DOR 1.1). No study reported the combination markers. No study reported UC versus OGD.
CD vs. UC (Seven Studies Included in Meta-analysis; Table 3) As shown in Table 3 and Figure 2 , for individual markers ASCA had the highest sensitivity of 56.6% Fig. 2 ). Anti-L had the second highest DOR for differentiating CD from UC (DOR 5.3; CI 3.3-8.6; two studies). 26, 27 The DORs for the other markers were also significantly greater than one: Anti-C, 3.5 (CI 2.1-5.7); ALCA, 3.5 (CI 2.7-4.5); AMCA, 2.6 (CI 1.7-4.2); and ACCA, 2.1 (CI 1.5-2.9). When a combination of positivity for 2 markers versus 1 was used to distinguish CD from UC, the DOR was 10.2 (CI 5.6-18.5; sensitivity 41.5%; specificity 92.8%; three studies). 17, 26, 28 A number of studies have reported marginal to no improvement in differentiation of CD from UC by adding other anti-glycan markers to gASCA and pANCA, 9,30 while others 26 reported that the addition of Anti-L and Anti-C to gASCA/pANCA significantly increased the discriminatory capacity for CD versus UC. The combination of two or more of these markers was better than any of the markers alone, although we could not tell which markers specifically contributed to the combination. On the other hand, it may not be necessary to specify the particular marker in the combination because of the low sensitivity of ALCA, ACCA, and AMCA.
Disease Phenotype
Of the 14 studies included in our systematic review, disease phenotype, (disease behavior and location) was defined by the Montreal Classification in six studies, 22, 24, 25, 27, 28, 30 Vienna classification in two studies, 17, 29 both Vienna and Montreal in four studies, 6,9,21,26 and was not specified in two studies.
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Disease Behavior
All nine studies included in the meta-analysis reported disease behavior, but only three studies reported their results in the quantitative detail necessary for inclusion in a meta-analysis. 9, 17, 26 All other studies reported the data qualitatively or gave only the direction of the relationship with a P-value. For the meta-analyses, we combined stricturing and penetrating/fistulizing disease into the category of complication. 9 One study was excluded from the meta-analysis of combination of markers because it included OmpC (non-anti-glycan) in the combination. 6 As shown in Table 3 and Figure  F3  3 , for individual markers ASCA had the highest sensitivity of 70.8% (specificity 48.5%), while ACCA had the highest specificity of 75.1% (sensitivity 43.3%). ACCA had the highest DOR of 2.7 (CI 6). None of the included studies provided data for this outcome for anti-L and anti-C. The pooled DOR for complications when a combination of 2 markers was used was 2.8 (CI 2.2-3.7; 2 studies), 9, 27 higher than any single marker alone (2.8 vs. 2.0), which shows a numerical, although not statistical tendency toward a higher chance of having a CD-related surgery.
In addition to the positivity(?), the levels of anti-glycan markers have also been analyzed for their association with disease behaviors or need for surgery. Higher serum levels of gASCA have been associated with stricturing and/ or penetrating behavior in literature. 27, 29, 30, 32 The relationship with rest of the anti-glycan markers is less clear, ranging from no association 32 to differing association. 17, 27, 29 A recently published review by Lakatos et al 33 reported that the likelihood of complicated CD behavior and CD-related surgery increases with the quartile score of the markers.
The other studies that documented the outcome, but could not be included in the meta-analysis, reported that the patients with stricturing or penetrating disease were more likely to have more than one positive anti-glycan marker. 6, 9, 17, 26, 27 Considering individual markers, there was an inconsistent association between CD behavior and the different anti-glycan markers in the studies. Rejchrt et al 31 found that the ALCA and ACCA positivity did not differ with disease phenotype or location. Rieder et al 24 reported a higher positivity for ASCA, AMCA, and Anti-L antibody markers in naïve patients (defined as patients with no complications [fistula, stenosis] or surgery before or within 20 days of sample procurement) progressing to a first complication event or IBD-related surgery. The median time to complication as well as surgery was 11.6 months. They also reported a higher likelihood for early progression to a disease event in patients positive for ASCA, AMCA, ACCA, and Anti-L. Koutroubakis et al 28 found ASCA and ALCA to be significantly associated with disease phenotype, but no association with AMCA and ACCA. Rieder et al 24 reported that CD patients positive for at least two out of the six antiglycan markers had a higher likelihood for complications and a more severe disease course. Our review of the literature suggests similarly that an increasing number of positive markers was associated with more aggressive disease and CD-related surgery. 6, 9, 17, 26, 27 Longer disease duration (see more details below), ileal involvement (see more in Disease Location, below), and the number of positive serological markers have been reported as independent predictors of stricturing/penetrating disease behavior. 6 
Age at Diagnosis and Disease Duration
Seow et al 27 reported an increasing number of positive antibodies to be associated with early age of CD diagnosis (P ¼ 0.0004) and longer disease duration (P ¼ 0.005). They also found an independent association between gASCA and early disease onset (OR 1.74, 95% CI 1.12-2.52; P ¼ 0.0035) and longer disease duration (OR 2.63, 95% CI 1.09-6.34; P ¼ 0.03). Ferrante et al 9 reported significantly longer disease duration in patients who were positive for gASCA, ACCA, AMCA, or OmpC (but not ALCA) compared to those who were negative for these serological markers. However, gASCA (P < 0.0001) and ALCA (P ¼ 0.012) were shown by Papp et al 6 to be associated with younger age at onset, but not with disease duration (the percentage of serological marker positivity not different between patients with <10 and 10 years disease duration). Malickova et al 30 reported a different frequency of gASCA between the four different groups of CD patients in their study, divided according to disease duration, but not variation of AMCA, ALCA, and ACCA with disease duration.
Surgery
Of seven studies reported, 6, 9, 17, [26] [27] [28] [29] three qualified for the meta-analysis. 6, 9, 27 As shown in Table 3 and Figure  F4 4, individually ASCA had the highest sensitivity of 60.2%
(specificity 57.3%) for surgery, with ACCA having the highest specificity of 67.3% (sensitivity 46.1%). The DOR for CD-related surgery was similar for ASCA and ACCA, being 2.0 (CI 1.6-2.4). 6, 9, 27 When positivity for 2 markers was used for the outcome, the DOR was 2.8 (CI 2.2-3.6), 9, 27 which was higher than any of the individual markers.
Disease Location
All nine studies included in the meta-analysis reported this outcome, but we could not do a meta-analysis for this outcome as the data were not in a retrievable form for meta-analysis. Independently, in the included studies it was found that the relationship between positivity of antiglycan markers and disease location was highly inconsistent. Apart from gASCA, which was found to be consistently associated with ileal 26, 28, 29 or ileocolonic CD, 27, 30 the association of other anti-glycan markers with disease localization in CD varied, to almost no association between ACCA, ALCA, or AMCA and CD localization. 30 Seow et al 27 reported that only gASCA IgA (20.4 vs. 6.0%, P < 0.001) and anti-L (14.3 vs. 3.3%, P < 0.001) were able to differentiate isolated inflammatory colonic CD from UC. However, Ferrante et al 9 demonstrated gASCA, ALCA, ACCA, and OmpC to be independently associated with ileal involvement (P-values of 0.010, 0.033, 0.044, and 0.044, respectively). Perianal disease is often seen as a different subset of CD than abdominal disease. The presence of perianal disease alone (B1p) was reported to be associated with a higher frequency of glycan antibodies compared with the absence of complicated disease behavior (B1). 26 AMCA and anti-C were reported to be independently associated with perianal disease. 27 
ASCA-negative Patients
Another benefit of adding these novel anti-glycan antibody markers to gASCA alone may be to diagnose CD in patients otherwise negative for gASCA. Studies have reported 32%-56% of their gASCA-negative patients positive for at least one of the three anti-glycan antibody markers AMCA, ALCA, and ACCA. 9, 17, 29, 30 The information could not be meta-analyzed due to lack of available data from the included studies.
Association of Genotypes with Serological Antiglycan Markers
One of the most intriguing observations regarding anti-glycan IBD biomarkers is a potential association of these serological markers with the genetic markers, the variants of IBD susceptible genes. At least four studies, 6, 21, 22, 34 first reported by Henckaerts et al 21 and later by Papp et al 6 and Lakatos et al 22, 34 examined the influence of mutations in several IBD susceptible genes on the development of anti-glycan in IBD, including AQ1 NOD2/CARD15, NOD1/CARD4, CARDINAL/CARD8, Toll-like receptors (TLRs; TLR1, TLR2, TLR4, and TLR6), DLG5, and DEFB1.
In Henckaerts et al's study, 21 gASCA or ALCA positivity in CD patients with at least one NOD2/CARD15 variant was significantly more frequent than those with no mutation (gASCA: 66.1% vs. 51.5%, P < 0.0001; ALCA: 43.3% vs. 34.9%, P ¼ 0.018). The gASCA titers were also higher in CD patients with NOD2/CARD15 mutations than those with no mutation (85.7 vs. 51.8 enzyme-linked immunosorbent assay [ELISA] units, P < 0.0001). A remarkably similar ASCA association with NOD2/CARD15 was reported by Papp et al. 6 In addition to ASCA, the positivity of AMCA in CD patient with NOD2/CARD15 mutations was 2-fold higher than those with no wildtype (WT) alleles (18.8% vs. 9.7%; P ¼ 0.009). 6 More intriguingly, both studies 6,21 observed a gene dosage effect when positivities of anti-glycan antibodies in CD patients carrying 0, 1, and 2 NOD2/CARD15 variants were compared: Positivity frequencies of anti-glycan markers (gASCA, ALCA, AMCA) increased gradually with increasing number of NOD2/ CARD15 mutations (see review 35 ). CD patients with a NOD1/CARD4 GG-indel allele exhibited significantly higher gASCA prevalence when compared with those with the WT allele (63.8% vs. 55.2%, P ¼ 0.014). 21 In contrast to NOD2, an inverse gene dosage effect of TLR4 on ACCA was observed by Henckaerts et al 21 :
The prevalence of ACCA in CD patients with 0, 1, and 2 TLR4 variants is 34.9%, 24.8%, and 9.1%, respectively. Two DEDB1 variants, G20A and C44G, were also found to be inversely associated with the positivity of antiglycan antibodies. 22 It is necessary to note that there is inconsistency among different studies with regard to the association of genetic markers with anti-glycan markers. For example, in studies by Lakatos et al, 22, 34 no significant association was found of NOD2, TLR4, NOD1, and DLG5 with the positivity of any anti-glycan markers.
Stability of Markers over Time
We found three published studies [24] [25] [26] by the same group on this subject, one of which was recently published. They reported substantial changes in the levels of the antibodies in their patients over time, but the status of the markers remained stable over time in terms of positivity or negativity for an anti-glycan biomarker antibody. The authors attributed the fluctuations to unidentified clinical factors, genotypes, or natural changes over time. They also sent out a word of caution on using the Quartile Serum Score for disease stratification due to these strong fluctuations in marker levels.
Applicability of Anti-glycan Markers in UC
Anti-glycan antibodies were generally considered markers specific for CD and thus useful for differentiating CD from UC. Malickova et al 30 reported that none of the assessed anti-glycan markers was predictive of colonic CD or UC and did not report more detailed data for this reason. Papp et al 6 also reported that no clinically important serotype-phenotype associations were seen in UC, for which the data were not presented. Ferrante et al 9 reported that gASCA, ACCA, and AMCA were inversely associated with UC-like disease behavior among CD patients, but no data were reported. This is the first study to employ meta-analytical techniques to assess the diagnostic and predictability value of these anti-glycan markers in IBD. Although narrative reviews have been previously published, 18, [32] [33] [34] [35] much of the existing literature on the subject is based on individual studies. Inevitable biases are introduced by pooling different observational studies, reflected by the statistical heterogeneity present throughout the analysis. All the included studies in this systematic review and meta-analysis were retrospective in nature. Although two studies 24, 25 claimed to have prospectively analyzed the patients, they did retrospective chart reviews to update their data points over time, and their results may be considered different from the other included cross-sectional studies. The observed heterogeneity in our analysis could be due to various sources including different cutoffs used for marker positivity, disease duration, various therapies, age at diagnosis, smoking habit, role of family history, sex, and body mass index (BMI). The source of control populations in the different studies was not clearly defined, and it was not explicitly stated whether the healthy controls and patients had been screened for IBD before or during recruitment. Most of studies included in our review presumably studied Caucasian populations (European subcontinent and Canada), except one study from Israel, 17 which studied a Jewish population, and the yield for the different markers could vary according to ethnicity.
RESEARCH LIMITATION/FUTURE STUDIES NEEDED
We found a number of research limitations during our review of the existing literature on the role of anti-glycan markers in IBD, which could potentially pave the path for the future studies on this subject.
Need for Prospective Studies
The retrospective design of the studies precludes any analysis of these markers for their predictive ability, for diagnostic outcomes as well as disease course. The statistical analysis in these retrospective studies is influenced by the composition of the study population, which was of patients already diagnosed, and therefore the performance of these markers is influenced by the pretest probability.
Influence of IBD Genetic Markers / IBD Susceptible Genes on Serological Anti-glycan Biomarkers
As described above, although data are limited, there is clear indication that genetic markers have significant influence on the prevalence and/or levels of anti-glycan markers in CD patients. Current inconsistency between different studies may arise from the differences in samples sizes and/or ethnic backgrounds of study cohorts. In the era when a fast-expanding number of IBD susceptible genes (both in CD and UC) have been identified by genome-wide association studies (GWAS), [36] [37] [38] future studies are absolutely necessary to analyze the association of these genetic markers with serological biomarkers (both anti-glycan and other biomarkers) in both CD and UC. This can be achieved only with much larger patient cohorts than what have been done currently, through close collaboration between major IBD centers, or the NIDDK IBD Genetic Consortium, a highly successful study group responsible for identifying most of the major IBD susceptible genes [36] [37] [38] (see http://medicine.yale.edu/intmed/ibdgc/index.aspx). A combination of genetic and serological biomarkers, if successful, may potentially revolutionize the way IBD diagnosis and management are currently performed.
Benefit of Marker Combination
The included studies combined various markers for knowing the combined efficacy, but did not specifically name the combinations, and as such we would not know which combination works the best or if there is some major driving marker among all the measured markers. ASCA had greatest predictive power. Since the incremental benefit of multiple markers was small compared to ASCA alone, it is important to know if ASCA was included in the combination of markers and if addition of other markers provided only marginal improvement in predictability compared to ASCA alone.
Influence of Ethnic Backgrounds
We have evidence that showed significant sensitivity and specificity of these anti-glycan markers in AfricanAmericans compared with those of Caucasians (DDW Abstract #1041828). However, there is no published study aimed at comparing the diagnostic values of these markers or their association with disease complication among subgroups of subjects with different race/ethnicity/ancestry.
Pediatric Population
No data are provided on the performance of this marker group in the pediatric age group. Only one study 27 that met the inclusion criteria included a pediatric population, but did not report them separately from adults, which could also be a source of potential heterogeneity in the study.
Marker Stability
Only three studies, from the same group, [24] [25] [26] looked into the stability of these markers over time, and more studies would be needed to truly prospectively follow these markers over time.
Effect of Therapy on Marker Positivity and Levels
We do not know whether these markers change, in positivity or level, with intervention, medical or surgical, which needs to be addressed in prospective studies.
Anti-glycan markers in Indeterminate Colitis (IC)
IC, comprising 10%-15% of all IBD patients, 39, 40 has either not been reported at all or purposefully excluded, citing low patient numbers.
In conclusion, ASCA had the highest diagnostic value among individual anti-glycan markers, while ACCA had the highest association with complications. For risk of surgery, ASCA and ACCA perform equally well. Although a combination of 2 markers was reported to be better in diagnosis and prognosis in most of the individual studies, we found the combination performing slightly better than any individual marker in our meta-analysis.
